Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(03): 139-141
DOI: 10.1590/0004-282X20170010
ARTICLE

Malignant multiple sclerosis: clinical and demographic prognostic factors

Esclerose múltipla maligna: fatores prognósticos clínicos e demográficos
Fabrício Hampshire-Araújo
1   Universidade Federal do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil;
,
Anke Bergmann
2   Instituto Nacional de Câncer, Rio de Janeiro RJ, Brasil;
,
Regina Maria Papais Alvarenga
3   Hospital Federal da Lagoa, Departamento de Neurologia, Rio de Janeiro RJ, Brasil;
4   Hospital Universitário Gaffree e Guinle, Departamento de Neurologia, Rio de Janeiro RJ, Brasil.
,
Cláudia Cristina Ferreira Vasconcelos
1   Universidade Federal do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil;
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Patients with malignant multiple sclerosis (MMS) reach a significant level of disability within a short period of time (Expanded Disability Status Scale score of 6 within five years). The clinical profile and progression of the disease were analyzed in a Brazilian cohort of 293 patients. Twenty-five (8,53%) patients were found to have MMS and were compared with the remaining 268 (91,47%). Women, non-white patients, older age at disease onset, shorter intervals between the first attacks, and more attacks in the first two years of the disease were all more common in the MMS group. These findings could serve as prognostic factors when making therapeutic decisions.

RESUMO

Os doentes com esclerose múltipla maligna (EMM) atingem um nível significativo de incapacidade dentro de um curto período de tempo (EDSS 6 em até 5 anos desde primeiro sintoma/sinal da doença). O perfil clínico e progressão da doença foram analisados em uma coorte brasileira de 293 pacientes. Vinte e cinco (8,53%) pacientes foram encontrados com EMM e foram comparados com os restantes 268 (91,47%). Mulheres, pacientes não-brancos, idade mais avançada no início da doença, intervalos mais curtos entre os primeiros ataques e, mais ataques nos dois primeiros anos da doença, foram mais comuns no grupo com EMM. Estes achados podem servir como fatores prognósticos na tomada de decisão terapêutica.

multiple sclerosis - disease progression
esclerose múltipla - progressão da doença


Publication History

Received: 08 August 2016

Accepted: 21 November 2016

Article published online:
05 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-85. https://doi.org/10.1056/NEJM199801293380502
  • 2 Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(3):393-9. https://doi.org/10.1093/brain/120.3.393
  • 3 Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011;76(23):1996-2001. https://doi.org/10.1212/WNL.0b013e31821e559d
  • 4 Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(11):1192-8. https://doi.org/10.1136/jnnp-2013-304951
  • 5 Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840-6. https://doi.org/10.1002/ana.20703
  • 6 Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11(7):379-89. https://doi.org/10.1038/nrneurol.2015.8
  • 7 Rahmlow MR, Kantarci O. Fulminant demyelinating diseases. Neurohospitalist. 2013;3(2):81-91. https://doi.org/10.1177/1941874412466873
  • 8 Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol. 2009;5(12):672-82. https://doi.org/10.1038/nrneurol.2009.178
  • 9 Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914-29. https://doi.org/10.1093/brain/awq118
  • 10 Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(3):606-16. https://doi.org/10.1093/brain/awl007